Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence
收藏NIAID Data Ecosystem2026-03-08 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2156727
下载链接
链接失效反馈官方服务：
资源简介：
The objective is to compare the efficacy and safety of masitinib at 4.5 mg/kg/day to placebo in the treatment of patients with localized, primary gastrointestinal stromal tumor (GIST) after complete surgery and with high risk of recurrence.
创建时间：
2015-07-15
